| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02200406 | Depression|Opioid Dependence|Methadone Treatment | Drug: Desvenlafaxine | Didier Jutras-Aswad|Pfizer|Centre hospitalier de l'Universit de Montral (CHUM) | Phase 4 | 2014-07-01 | 2016-09-01 |
| NCT00888862 | Major Depressive Disorder|Menopausal Staging and Vasomotor Symptoms (for Females) | Drug: Desvenlafaxine Succinate | Hamilton Health Sciences Corporation|Wyeth is now a wholly owned subsidiary of Pfizer|St. Joseph's Healthcare Hamilton|McMaster University | Phase 3 | 2009-06-01 | 2012-02-07 |
| NCT01948895 | Dysthymic Disorder | Drug: Desvenlafaxine | Centre for Addiction and Mental Health | | 2012-08-01 | 2014-11-06 |
| NCT01974934 | Vascular Depression | Drug: Desvenlafaxine Succinate | Hotel-Dieu Grace Healthcare | Phase 4 | 2013-12-01 | 2015-03-18 |
| NCT02819921 | Hot Flashes|Breast Neoplasms | Drug: Desvenlafaxine succinate|Drug: Placebo | Seoul National University Hospital|Seoul National University Bundang Hospital|Korea Cancer Center Hospital|Pfizer | Phase 4 | 2016-09-01 | 2016-06-28 |
| NCT00818155 | Healthy | Drug: desvenlafaxine succinate SR|Other: Placebo | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2009-01-01 | 2013-01-28 |
| NCT01537068 | Dysthymic Disorder|Dysthymia|Chronic Depressive Disorder | Drug: Desvenlafaxine|Drug: Placebo | New York State Psychiatric Institute|Pfizer | Phase 4 | 2012-02-01 | 2015-04-13 |
| NCT01188668 | Pharmacokinetics|Cytochrome P-450 CYP2D6|CYP3A4 Protein, Human | Drug: Aripiprazole|Drug: Aripiprazole + desvenlafaxine succinate sustained release | Pfizer | Phase 4 | 2010-08-01 | 2011-11-01 |
| NCT02859103 | Depression|Anhedonia | Drug: Desvenlafaxine | St. Michael's Hospital, Toronto | Phase 4 | 2016-11-01 | 2016-08-03 |
| NCT01316302 | Social Anxiety Disorder | Drug: Pristiq|Drug: Placebo | The Medical Research Network|Pfizer | Phase 4 | 2011-04-01 | 2016-08-23 |
| NCT01353963 | Major Depressive Disorder|Vasomotor Symptoms | Drug: desvenlafaxine succinate | Pfizer | Phase 4 | 2012-03-01 | 2015-12-04 |
| NCT01527786 | Depression | Drug: Desvenlafaxine | BC Women's Hospital & Health Centre | Phase 3 | 2010-11-01 | 2015-01-26 |
| NCT01432457 | Major Depressive Disorder | Drug: desvenlafaxine succinate sustained-release 50 mg/day|Drug: desvenlafaxine succinate sustained-release 100 mg/day|Drug: placebo | Pfizer | Phase 4 | 2011-10-01 | 2013-12-17 |
| NCT00831415 | Major Depressive Disorder | Drug: desvenlafaxine succinate sustained release tablets | Pfizer | Phase 3 | 2009-03-01 | 2011-12-22 |
| NCT02988024 | Major Depression | Drug: LY03005|Drug: Pristiq | Luye Pharma Group Ltd. | Phase 1 | 2016-12-07 | 2017-03-17 |
| NCT01189500 | Pharmacokinetics | Drug: Tamoxifen|Drug: Tamoxifen and Desvenlafaxine Succinate Sustained Release | Pfizer | Phase 4 | 2010-08-01 | 2011-11-01 |
| NCT00824291 | Depressive Disorder, Major | Drug: desvenlafaxine succinate sustained release|Genetic: Genotyping | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2009-02-01 | 2011-03-04 |
| NCT01443208 | Major Depressive Disorder | Drug: desvenlafaxine|Drug: desvenlafaxine|Drug: desvenlafaxine | Pfizer | Phase 1 | 2011-11-01 | 2011-12-29 |
| NCT01101152 | Healthy | Drug: Desvenlafaxine succinate | University of Ottawa | Phase 1 | 2010-04-01 | 2011-08-04 |
| NCT01803711 | Major Depression|Cancer|Diabetes|Cardiovascular Diseases | Drug: Desvenlafaxine|Dietary Supplement: Omega 3 Fatty acids|Drug: Placebo (for Omega 3 fatty acid supplement) | UConn Health | Phase 2|Phase 3 | 2013-02-01 | 2016-03-03 |
| NCT01492621 | Major Depression | Drug: Desvenlafaxine | Centre de recherche Fernand-Seguin, H么pital Louis-H. Lafontaine|Pfizer | Phase 4 | 2011-11-01 | 2011-12-14 |
| NCT01977378 | Major Depressive Disorder | Drug: Sustained-Release Desvenlafaxine Hydrochloride|Drug: Sustained-Release Venlafaxine Hydrochloride | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2|Phase 3 | 2013-10-01 | 2013-10-30 |
| NCT01121484 | Major Depressive Disorder | Drug: desvenlafaxine succinate sustained-release|Drug: placebo | Pfizer | Phase 4 | 2010-06-01 | 2012-03-30 |
| NCT01221935 | Major Depressive Disorder | Other: Pristiq first-line treatment charts|Other: Pristiq second-line treatment charts|Other: SNRI or SSRI first-line treatment charts|Other: SNRI or SSRI second-line treatment charts | Pfizer | Phase 4 | 2009-09-01 | 2011-01-25 |
| NCT00887224 | Major Depressive Disorder | Drug: Desvenlafaxine succinate sustained release 50 mg|Drug: Desvenlafaxine succinate sustained release 25 mg|Drug: Placebo | Pfizer | Phase 3 | 2009-06-01 | 2014-11-06 |
